Overview

Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment

Status:
Completed

Trial end date:
2012-08-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works in treating patients with or metastatic urothelial cancer or bladder cancer that has relapsed or not responded to treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Treatments:

Fluorodeoxyglucose F18